Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · February 15, 2018

Intrathecal Trastuzumab in HER2+ Breast Leptomeningeal Disease

Breast Cancer Research and Treatment

 

Additional Info

Disclosure statements are available on the authors' profiles:

Breast Cancer Research and Treatment
Intrathecal Trastuzumab in the Management of HER2+ Breast Leptomeningeal Disease: A Single Institution Experience
Breast Cancer Res Treat 2018 Feb 01;[EPub Ahead of Print], NB Figura, W Long, M Yu, TJ Robinson, S Mokhtari, AB Etame, ND Tran, R Diaz, H Soliman, HS Han, S Sahebjam, PA Forsyth, KA Ahmed

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading